Background Estrogen administration in postmenopausal women is associated with a 50% reduction in the clinical manifestations of coronary artery disease. The mechanisms are not known, although one potential explanation is estrogen-induced modulation of coronary vasoreactivity. Acetylcholine is an endothelium-dependent vasodilator that may be used to assess coronary vasoreactivity and elicits coronary responses that parallel those found with common daily vasomotor stimuli. Therefore, we tested whether estrogen attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women.
Methods and Results Acetylcholine-induced changes in coronary flow, resistance, and cross-sectional area were determined before and 15 minutes after intravenous administration of ethinyl estradiol (EE, 35 ,ug) in 15 postmenopausal women. The influence of estrogen on basal coronary flow, resistance, and epicardial cross-sectional area was also assessed by measuring these parameters before and after EE or placebo administration in 33 women. Estrogen altered basal coronary vasomotor tone in 22 women as manifested by an EE-induced 23.3 ±4.5% (mean±SEM) increase (P<.01) in coronary flow, a 15.0±3.2% decrease (P<.01) in resistance, and a 20.0±6.5% increase (P=.02) in epicardial cross-sectional area. Placebo administration in 11 women did not change these parameters. strogen administration in postmenopausal E women is associated with a nearly 50% reduction in the development of clinical manifestations of coronary artery disease.' The mechanism of the cardioprotective effect of estrogen, however, has not been completely defined. Although estrogen has been shown to favorably alter the lipid profile2-5 and inhibit endothelial hyperplasia,6 these effects do not fully account for the degree of clinical benefit attributed to estrogen therapy. Another proposed mechanism of the cardioprotective effect of estrogen is favorable modulation of coronary vasoreactivity. This is suggested by studies that have demonstrated the ability of estrogen to block endothelin-1 and calcium-mediated vasoconstriction in isolated coronary arteries,7,8 stimulate prostacyclin production,9'10 and modulate the production of nitric oxide," an endothelium-derived vasoactive inter-mediary that induces vascular smooth muscle relaxation and vasodilatation and inhibits vascular smooth muscle cell proliferation and mitogenesis. 12 Acetylcholine induces arterial dilatation via endothelial production of nitric oxide.13 In arteries with disrupted endothelium, however, acetylcholine induces paradoxical vasoconstriction due to a direct constrictor effect on arterial smooth muscle cells. Therefore, acetylcholine may be used to assess the functional integrity of vascular endothelium. The vasomotor response of coronary arteries to acetylcholine parallels the response to common daily vasomotor stimuli such as exercise and mental stress. '4,15 Estrogen attenuates abnormal acetylcholine-induced coronary vasoconstriction in hypercholesterolemic ovariectomized cynomolgus monkeys with coronary intimal hyperplasia.16,17 Therefore, estrogen may favorably influence abnormal coronary vasoreactivity in postmenopausal women by attenuating the inappropriate coronary vasoconstrictor response to common neurohumoral endothelium-dependent vasodilator stimuli that occurs in patients with coronary disease.' 141518 This may provide an explanation for the clinical cardioprotective effect of estrogen, since abnormal coronary vasoreactivity has been impli-cated in the pathogenesis of unstable angina,'9-22 acute myocardial infarction,23 and sudden death. 24 We hypothesized that estrogen has acute in vivo vascular properties that alter basal coronary vasomotor tone and modulate inappropriate coronary vasoreactivity in both coronary conductance and resistance vessels in postmenopausal women. We examined this hypothesis by using intracoronary Doppler ultrasonography and quantitative coronary angiography to assess the coronary artery cross-sectional area, flow, and resistance responses to a single dose of estrogen in the absence of vasoactive stimuli and in the presence of acetylcholine, an endothelium-dependent vasodilator. 
Methods

Determination of Effects of Estrogen on Coronary Response to Acetylcholine
Acetylcholine is an endothelium-dependent vasodilator that induces dilation of coronary resistance and conductance vessels when administered in doses that achieve coronary concentrations of <10-6 mol/L.1326 Coronary resistance vessel dilatation is manifested by increased coronary blood flow and decreased resistance, whereas conductance vessel dilatation is characterized by increased epicardial cross-sectional area. To assess the effects of estrogen on the coronary responses to acetylcholine, the last 15 consecutive subjects who were to receive estrogen were given intracoronary infusions of acetylcholine before and after intravenous ethinyl estradiol administration. A 5F pacing wire was prophylactically placed in the right ventricle before acetylcholine administration. Baseline coronary hemodynamic parameters were obtained during the infusion of normal saline via a coronary catheter engaged in the LMCA or RCA at a rate of 2 mL/min for 2 minutes. This infusion controlled any vasoactive effects of the infusion rate and the diluent used to prepare acetylcholine. Intracoronary acetylcholine was administered in doses of 0.29 and 2.9 jig at a rate of 2 mL/min for 2 minutes. These doses were given to achieve estimated coronary blood acetylcholine concentra- Nitroglycerin is an endothelium-independent agent that acts directly on coronary arterial smooth muscle cells to induce vasodilatation by increasing production of cGMP and lowering intracellular calcium levels. The coronary hemodynamic effects of intracoronary nitroglycerin were assessed to determine whether differences in the vasomotor responses to acetylcholine were due to differences in intrinsic coronary smooth muscle cell vasodilator capacity. Coronary cross-sectional area and absolute flow were determined as previously described before and immediately after administration of an intracoronary bolus of nitroglycerin (200 gg) in the study artery at the conclusion of the protocol.
Statistical Analysis
The data are expressed as mean±SEM and are analyzed using the sPss/PC+ v4.0 computational statistical package (SPSS, Inc, Chicago, Ill). Values of P<.05 were considered significant. The subjects were divided into two groups for analysis: those who received intravenous ethinyl estradiol (group 1) and those who received an intravenous placebo (group 2). Subject characteristics were compared between the two groups using the independent Student's t test for continuous data and X2 analysis for categorical data. Comparisons of coronary flow, resistance, cross-sectional area, blood pressure, and heart rate before and after intravenous ethinyl estradiol or placebo were performed using the paired Student's t test. Changes in hemodynamic parameters associated with ethinyl estradiol and placebo were compared between groups using the independent t test.
Subjects who received acetylcholine were divided into two groups for analysis on the basis of their coronary flow response to acetylcholine. Eight of the subjects exhibited the expected coronary flow augmentation in response to acetylcholine, indicating normally functioning coronary resistance vessel endothelium. Seven subjects exhibited a reduction in coronary flow in response to acetylcholine, indicating abnormal resistance vessel endothelial function. The influence of ethinyl estradiol on the coronary flow and resistance responses to acetylcholine were examined and compared separately in these two groups by use of the paired Student's t test. Basal hemodynamic parameters and the changes induced by acetylcholine were compared between these two groups by use of the independent t test.
Coronary resistance vessel response to acetylcholine does not predict the vasomotor response of proximal epicardial conductance vessels to acetylcholine.13 Therefore, a similar analysis was performed by dividing the 15 women who received acetylcholine into two groups defined by their epicardial crosssectional area response to acetylcholine. Cross-sectional area response is based on the measurement of cross-sectional area at a fixed anatomic coordinate determined by its location relative to a branch point. This location is different from that of the cross-sectional area measurement used to calculate coronary blood flow. Eight of the subjects exhibited normal acetylcholine-induced epicardial vasodilatation suggestive of normal conductance vessel endothelial function, whereas seven had paradoxical epicardial constriction in response to acetylcholine consistent with conductance vessel endothelial dysfunction.
Results
Patient Characteristics
Thirty-three postmenopausal women were studied; of these, 22 received intravenous ethinyl estradiol (group 1), and 11 received an intravenous placebo (group 2). There were no significant differences between the groups with respect to known and proposed factors that may affect coronary vasomotor function (Table 1) . These include age, number of years since menopause, levels of total, low-density lipoprotein (LDL), and highdensity lipoprotein (HDL) cholesterol, systolic and diastolic blood pressures, heart rate, and the extent of coronary artery disease. The proportions of subjects in group 1 who had their LAD (7 of The coronary conductance vessel response to acetylcholine is dependent on the endothelial integrity of the studied epicardial segment and does not necessarily parallel the resistance vessel response to acetylcholine. Therefore, the 15 consecutive subjects who received acetylcholine were grouped with respect to their proximal epicardial coronary vasodilator response to acetylcholine. Eight women with angiographically normal-appearing epicardial coronaries had a normal vasodilator response to acetylcholine, whereas seven others with minor epicardial irregularities (maximum percentage of diameter stenosis, 18.3±11.9%) had paradoxical acetylcholine-induced vasoconstriction in a normal-appearing proximal coronary segment. These groups were similar with respect to age, number of years since menopause, total, LDL, and HDL cholesterol levels, systolic and diastolic blood pressures, heart rate, vessel studied, and baseline cross-sectional area (Table 6 ).
The eight women with normal conductance vessel endothelial function demonstrated a 25.3±4.9% (P=.02) increase in epicardial cross-sectional area, from 0.052±0.012 to 0.066±0.015 cm2, in response to acetylcholine (Table 7) . Fifteen minutes after ethinyl estradiol administration, these epicardial segments had a similar 25.7±4.0% (P=.02) increase in cross-sectional area, from 0.062±0.012 to 0.079±0.016 cm2, in response to acetylcholine, suggesting that ethinyl estradiol did not affect the acetylcholine response of these normally functioning conductance vessels.
The seven women with dysfunctional conductance vessel endothelium had an acetylcholine-induced 14.2±4.4% (P=.04) decrease in epicardial cross-sectional area from 0.047±0.008 to 0.041±0.008 cm2. Fifteen minutes after ethinyl estradiol administration in these women, however, intracoronary acetylcholine no longer induced abnormal epicardial constriction (from 0.050±0.008 to 0.051±0.009 cm2, P=NS). The acetylcholine-induced conductance vessel responses before and after ethinyl estradiol administration were significantly different (P=.02), suggesting that ethinyl estradiol attenuated the dysfunctional epicardial conductance vessel endothelial response to acetylcholine. These two groups of women with normal and abnormal conductance vessel endothelial function had similar increases in epicardial cross-sectional area in response to nitroglycerin (71.8±36.6% versus 56.1±28.3%, P=NS), suggesting that coronary conductance vessel ACh indicates acetylcholine; CSA, cross-sectional area; LDL, low-density lipoprotein; HDL, high-density lipoprotein; BP, blood pressure; normal, ACh-induced epicardial coronary vasodilatation; abnormal, ACh-induced epicardial coronary vasoconstriction; bpm, beats per minute; LAD, left anterior descending coronary artery; LCx, left circumflex artery; and RCA, right coronary artery. Values are mean±SEM.
There were no significant differences in subject characteristics between the study groups.
Discussion
The present study demonstrates that ethinyl estradiol has in vivo coronary vasoactive properties that decrease basal coronary resistance and conductance vessel vasomotor tone and attenuate abnormal coronary hemodynamic responses to acetylcholine in postmenopausal women. Under basal conditions, ethinyl estradiol administration was associated with a mean 23.3% increase in coronary blood flow and a 15.0% decrease in coronary resistance, suggesting that it induced resistance vessel dilatation. Ethinyl estradiol administration was also associated with coronary conductance vessel dilatation as manifested by a 20.0% increase in epicardial coronary cross-sectional area. In contrast, intravenous placebo was not associated with changes in basal coronary hemodynamics.
Ethinyl estradiol also attenuated paradoxical changes in coronary resistance and conductance vessel hemodynamics in response to the endothelium-dependent vasodilator acetylcholine. Before ethinyl estradiol administration, acetylcholine induced a mean 33 These results suggest that estrogen directly affects basal coronary resistance vessel tone, which, in the absence of significant epicardial stenoses, regulates coronary vascular resistance and blood flow. The demonstrated vasodilatory effect of estrogen on conductance vessels, however, may be due to either a direct effect of estrogen on epicardial coronary arteries or to an indirect effect via flow-mediated dilatation. Cox et a127 have reported that coronary flow augmentation, resulting from resistance vessel dilatation caused by distal coronary infusion of adenosine, is an endothelium-dependent stimulus that induces dilatation of proximal coronary conductance vessels. This may result from increased flow inducing changes in proximal arterial shear stress.28,29 Therefore, estrogen-induced resistance vessel vasodilatation may indirectly induce conductance vessel dilatation.
The vascular effects of estrogen may be mediated on a cellular level by a direct interaction with arterial smooth muscle cells, by the production of humoral vasoactive substances, and/or by modulation of vascular endothelium, which synthesizes and releases vasoactive intermediaries. Animal aortic smooth muscle cells contain cytoplasmic and nuclear estrogen receptors. [30] [31] [32] [33] Administration of 17,B-estradiol to oophorectomized baboons and male rats is associated with a decrease in cytoplasmic estrogen receptor content and a concomitant increase in nuclear estrogen receptor content,30,31 suggesting that estrogen modulates receptor physiology. However, the functional role of these arterial myocyte estrogen receptors is not known.
Estrogen has also been shown to influence electrical properties of vascular smooth muscle cells in a manner that would be expected to result in vasodilation. Exposure of isolated canine coronary arteries to diethylstilbestrol results in dose-dependent cell membrane hyperpolarization and abolishes action potentials induced by field stimulation and/or exposure to tetraethylammonium chloride.34 These direct effects on electrical properties are believed to be mediated by an estrogen-induced increase in potassium conductance of the vascular smooth muscle cell.
Estrogen induces the production of humoral vasodilator substances by arterial myocytes, as demonstrated by 1713-estradiol-induced increases in the production of the prostacyclin metabolite 6-ketoprostaglandin F,, in rat aorta smooth muscle cell cultures9 and human umbilical vascular segments.10 In addition, estrogen antagonizes calcium-and endothelin-1-induced vasoconstriction, as manifested by rightward shifts of calcium concentration-and endothelin-1 concentrationdependent contraction curves of endothelium-denuded female rabbit coronary artery rings.8 These studies in normal arteries and arterial myocytes in experimental models strongly suggest a direct vascular relaxant effect of estrogen.
Another possible mechanism for the vasoactive properties of estrogen is stimulation of the production of endothelium-derived vasoactive intermediaries, such as nitric oxide, that act on arterial myocytes to induce vasodilatation. Van Several studies indicate that estrogen deficiency may contribute to abnormal endothelial function1617 and that estrogen administration may favorably alter the balance between coronary constriction and dilatation.7-l1,l6,l734 Acetylcholine is an endothelium-dependent vasodilator that can be used to assess endothelial function, since it induces dilatation of arteries with normal endothelium (by inducing nitric oxide production) and paradoxical vasoconstriction in arteries with disrupted endothelium (by a direct constriction effect on arterial smooth muscle cells). The coronary vasomotor response to acetylcholine mirrors the response to common daily physiological stimuli, such as exercise and mental stress, in the presence and absence of atherosclerosis and certain risk factors for arterial disease. [13] [14] [15] 18, 26, 35 42 The present study demonstrates that ethinyl estradiol attenuates abnormal coronary vasoreactivity in postmenopausal women, as manifested by paradoxical acetylcholine-induced responses of both resistance and conductance coronary arteries with dysfunctional endothelium. This finding extends those of Williams et al, 16 who demonstrated that intravenous ethinyl estradiol administration in ovariectomized cynomolgus monkeys decreases an abnormal vasoconstrictor acetylcholine response of atherosclerotic epicardial coronaries. One consequence of abnormal basal coronary vasomotor tone and abnormal coronary vasoreactivity in response to endothelium-dependent vasodilators is myocardial ischemia. Ischemia may occur in the setting of coronary flow reduction that is due to epicardial vasoconstriction superimposed on an already narrowed caliber in atherosclerotic vessels. The clinical relevance of this sequence is emphasized by its important role in the genesis of myocardial ischemia in patients with exercise-induced angina,14 unstable angina,'9-22 silent ischemia,43 myocardial infarction,23 and sudden death. 24 The present study is limited by its inability to identify the mechanism of the vasoactive effects of estrogen. The findings that ethinyl estradiol increases coronary flow and cross-sectional area and decreases resistance may be due to a direct effect on arterial myocytes or the production of endothelium-derived vasoactive intermediaries. In addition, the clinical relevance of these findings depends on the hemodynamic effects of ethinyl estradiol in coronary arteries with significant atherosclerotic disease, and only normal vessels or those with minimal irregularities were studied. Finally, the dose of ethinyl estradiol used in this study was identical to that present in a single oral contraceptive pill. This dose may be greater than the equivalent estrogen dose administered chronically in hormonal replacement regimens. Nevertheless, the present findings indicate that estrogen-induced alteration in the dynamic balance between myocardial oxygen supply and demand under basal conditions and in the presence of common neurohumoral vasoactive stimuli may be one mechanism for the cardioprotective effects of pharmacological estrogen therapy in postmenopausal women.
